Axonal damage in multiple sclerosis

Mount Sinai Journal of Medicine

Volumn 78, Issue 2, 2011, Pages 231-243

  Haines, Jeffery D ^a   Inglese, Matilde ^a   Casaccia, Patrizia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

axon; demyelination; multiple sclerosis; myelin; neurodegeneration; neuroimaging; oligodendrocyte; pathogenesis

Indexed keywords

AUTOANTIBODY; CYTOKINE; GLUTAMIC ACID; N ACETYLASPARTIC ACID;

ARTICLE; AXONAL INJURY; CELL HETEROGENEITY; CYTOKINE RELEASE; CYTOTOXICITY; DIAGNOSTIC IMAGING; DRUG TARGETING; GRAY MATTER; HISTOPATHOLOGY; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER;

ACTIVITIES OF DAILY LIVING; ADULT; ANIMALS; ASPARTIC ACID; AXONS; HUMANS; IMMUNITY; IMMUNOLOGIC FACTORS; INFLAMMATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE DEGENERATION; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY;

EID: 79953021632     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20246     Document Type: Article

References (145)

1. Weinshenker BG., Epidemiology of multiple sclerosis. Neurol Clin 1996; 14: 291-308. (Pubitemid 26157423)
2. Noseworthy JH, Lucchinetti C, Rodriguez M, et al,. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
3. Ebers GC., Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7: 268-277. (Pubitemid 351222732)
4. Trapp BD, Nave KA., Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247-269.
5. Rovaris M, Confavreux C, Furlan R, et al,. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5: 343-354.
6. Thompson AJ, Polman CH, Miller DH, et al,. Primary progressive multiple sclerosis. Brain 1997; 120 part 6 1085-1096. (Pubitemid 27259557)
7. Kornek B, Lassmann H., Axonal pathology in multiple sclerosis: a historical note. Brain Pathol 1999; 9: 651-656. (Pubitemid 29470958)
8. Brück W., Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J Neurol 2005; 252 suppl 5 v10-v15. (Pubitemid 41532350)
9. Brück W., The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005; 252 suppl 5 v3-v9. (Pubitemid 41532349)
10. De Vos KJ, Grierson AJ, Ackerley S, et al,. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008; 31: 151-173.
11. Saxena S, Caroni P., Mechanisms of axon degeneration: from development to disease. Prog Neurobiol 2007; 83: 174-191. (Pubitemid 47484043)
12. Williamson TL, Cleveland DW., Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 1999; 2: 50-56. (Pubitemid 30488940)
13. Koo EH, Sisodia SS, Archer DR, et al,. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A 1990; 87: 1561-1565.
14. Terwel D, Dewachter I, Van Leuven F., Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med 2002; 2: 151-165. (Pubitemid 37012502)
15. Bitsch A, Schuchardt J, Bunkowski S, et al,. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 2000; 123 part 6 1174-1183. (Pubitemid 30312109)
16. Ferguson B, Matyszak MK, Esiri MM, et al,. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120 part 3 393-399. (Pubitemid 27153632)
17. Watson DF, Fittro KP, Hoffman PN, et al,. Phosphorylation-related immunoreactivity and the rate of transport of neurofilaments in chronic 2,5-hexanedione intoxication. Brain Res 1991; 539: 103-109.
18. Su JH, Cummings BJ, Cotman CW., Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res 1996; 739: 79-87. (Pubitemid 26387365)
19. Nihei K, McKee AC, Kowall NW., Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol 1993; 86: 55-64. (Pubitemid 23249074)
20. Wegner C, Esiri MM, Chance SA, et al,. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67: 960-967. (Pubitemid 44454585)
21. Trapp BD, Peterson J, Ransohoff RM, et al,. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285. (Pubitemid 28065253)
22. Kornek B, Storch MK, Weissert R, et al,. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-276. (Pubitemid 30641742)
23. Evangelou N, Konz D, Esiri MM, et al,. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000; 123 part 9 1845-1849. (Pubitemid 30664287)
24. Patrikios P, Stadelmann C, Kutzelnigg A, et al,. Remyelination is extensive in a subset of multiple sclerosis patients [published correction appears in Brain 2007;130(part 3):879]. Brain 2006; 129: 3165-3172. (Pubitemid 44871433)
25. Bolton C, Paul C., Glutamate receptors in neuroinflammatory demyelinating disease. Mediators Inflamm 2006; 2006: 93684.
26. Lassmann H., Recent neuropathological findings in MS-implications for diagnosis and therapy. J Neurol 2004; 251 suppl 4 IV2-IV5.
27. Raine CS, Cross AH., Axonal dystrophy as a consequence of long-term demyelination. Lab Invest 1989; 60: 714-725. (Pubitemid 19154520)
28. Irvine KA, Blakemore WF., Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 2006; 175: 69-76. (Pubitemid 43765747)
29. Irvine KA, Blakemore WF., Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008; 131 part 6 1464-1477. (Pubitemid 351806463)
30. Siffrin V, Vogt J, Radbruch H, et al,. Multiple sclerosis: candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010; 33: 202-210.
31. Davies GR, Ramiõ-Torrentà L, Hadjiprocopis A, et al,. Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 998-1002. (Pubitemid 38869614)
32. Ramiõ-Torrentá L, Sastre-Garriga J, Ingle GT, et al,. Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry 2006; 77: 40-45. (Pubitemid 43022688)
33. De Stefano N, Matthews PM, Filippi M, et al,. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157-1162. (Pubitemid 36418778)
34. Peterson JW, Bø L, Mørk S, et al,. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400. (Pubitemid 32848742)
35. Bø L, Vedeler CA, Nyland H, et al,. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003; 9: 323-331. (Pubitemid 36958014)
36. Brink BP, Veerhuis R, Breij EC, et al,. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005; 64: 147-155. (Pubitemid 40349313)
37. Agosta F, Rovaris M, Pagani E, et al,. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006; 129: 2620-2627. (Pubitemid 44522095)
38. Fisniku LK, Chard DT, Jackson JS, et al,. Gray matter atrophy is related to long-term disability in multiple sclerosis [published correction appears in Ann Neurol 2009;65:232:]. Ann Neurol 2008; 64: 247-254.
39. Fisher E, Lee JC, Nakamura K, et al,. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255-265.
40. Rovaris M, Judica E, Gallo A, et al,. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 2006; 129: 2628-2634. (Pubitemid 44522096)
41. Manfredonia F, Ciccarelli O, Khaleeli Z, et al,. Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosis. Arch Neurol 2007; 64: 411-415. (Pubitemid 46425697)
42. Cifelli A, Arridge M, Jezzard P, et al,. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002; 52: 650-653. (Pubitemid 35246871)
43. Huizinga R, Gerritsen W, Heijmans N, et al,. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis 2008; 32: 461-470.
44. Magliozzi R, Howell O, Vora A, et al,. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089-1104. (Pubitemid 47355604)
45. Androdias G, Reynolds R, Chanal M, et al,. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 2010; 68: 465-476.
46. Frischer JM, Bramow S, Dal-Bianco A, et al,. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189.
47. Tallantyre EC, Bø L, Al-Rawashdeh O, et al,. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain 2009; 132: 1190-1199.
48. Griffiths I, Klugmann M, Anderson T, et al,. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998; 280: 1610-1613. (Pubitemid 28278256)
49. Lappe-Siefke C, Goebbels S, Gravel M, et al,. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 2003; 33: 366-374. (Pubitemid 36278853)
50. Yin X, Crawford TO, Griffin JW, et al,. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 1998; 18: 1953-1962. (Pubitemid 28141401)
51. Nave, KA., Myelination and the trophic support of long axons. Nat Rev Neurosci 2010; 11: 275-283.
52. Barkhof F., MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 1999; 5: 283-286. (Pubitemid 29405626)
53. Revesz T, Kidd D, Thompson AJ, et al,. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117 part 4 759-765. (Pubitemid 24281838)
54. Thompson AJ, Kermode AG, Wicks D, et al,. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53-62.
55. Confavreux C, Vukusic S, Moreau T, et al,. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
56. Coles AJ, Wing MG, Molyneux P, et al,. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304. (Pubitemid 29416266)
57. Sailer M, Fischl B, Salat D, et al,. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003; 126: 1734-1744. (Pubitemid 36917333)
58. Tartaglia MC, Narayanan S, Francis SJ, et al,. The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol 2004; 61: 201-207. (Pubitemid 38197551)
59. Gadea M, Martínez-Bisbal MC, Marti-Bonmatí L, et al,. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain 2004; 127: 89-98. (Pubitemid 38055348)
60. Pan JW, Krupp LB, Elkins LE, et al,. Cognitive dysfunction lateralizes with NAA in multiple sclerosis. Appl Neuropsychol 2001; 8: 155-160. (Pubitemid 32976967)
61. Riccitelli G, Rocca MA, Pagani E, et al,. Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. Hum Brain Mapp 2010; doi:10.1002/hbm.21125.
62. Gold SM, Kern KC, O'Connor MF, et al,. Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry 2010; 68: 553-559.
63. Semra YK, Seidi OA, Sharief MK., Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002; 122: 132-139. (Pubitemid 34075499)
64. Kapaki E, Paraskevas GP, Michalopoulou M, et al,. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000; 43: 228-232. (Pubitemid 30258988)
65. Lycke JN, Karlsson JE, Andersen O, et al,. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-404. (Pubitemid 28159853)
66. Malmeström C, Haghighi S, Rosengren L, et al,. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-1725. (Pubitemid 38020818)
67. Tumani H, Hartung HP, Hemmer B, et al,; BioMS Study Group. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009; 35: 117-127.
68. Tomassini V, Palace J., Multiple sclerosis lesions: insights from imaging techniques. Expert Rev Neurother 2009; 9: 1341-1359.
69. Vrenken H, Geurts JJ., Gray and normal-appearing white matter in multiple sclerosis: an MRI perspective. Expert Rev Neurother 2007; 7: 271-279. (Pubitemid 46434175)
70. Fisher E, Rudick RA, Simon JH, et al,. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-1420. (Pubitemid 35285996)
71. Rudick RA, Fisher E, Lee JC, et al,. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-1704. (Pubitemid 29530342)
72. Ceccarelli A, Rocca MA, Pagani E, et al,. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 2008; 42: 315-322.
73. Geurts JJ, Pouwels PJ, Uitdehaag BM, et al,. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005; 236: 254-260. (Pubitemid 40853320)
74. Kidd D, Barkhof F, McConnell R, et al,. Cortical lesions in multiple sclerosis. Brain 1999; 122 part 1 17-26. (Pubitemid 29046269)
75. Geurts JJ, Bø L, Pouwels PJ, et al,. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 2005; 26: 572-577. (Pubitemid 43085960)
76. Le Bihan D, Mangin JF, Poupon C, et al,. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001; 13: 534-546. (Pubitemid 32231507)
77. Behrens TE, Johansen-Berg H, Woolrich MW, et al,. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci 2003; 6: 750-757. (Pubitemid 36792891)
78. Filippi M, Cercignani M, Inglese M, et al,. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001; 56: 304-311. (Pubitemid 32144139)
79. Rovaris M, Iannucci G, Falautano M, et al,. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J Neurol Sci 2002; 195: 103-109. (Pubitemid 34202286)
80. Inglese M, Madelin G, Oesingmann N, et al,. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain 2010; 133: 847-857.
81. Waxman SG., Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 2006; 7: 932-941.
82. Arnold DL, Matthews PM, Francis G, et al,. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990; 14: 154-159. (Pubitemid 20243873)
83. Wolinsky JS, Narayana PA, Fenstermacher MJ., Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990; 40: 1764-1769. (Pubitemid 20383148)
84. Simmons ML, Frondoza CG, Coyle JT., Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
85. De Stefano N, Battaglini M, Smith SM., Measuring brain atrophy in multiple sclerosis. J Neuroimaging 2007; 17 suppl 1 10S-15S. (Pubitemid 46558262)
86. De Stefano N, Narayanan S, Francis GS, et al,. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70. (Pubitemid 32053209)
87. Matthews PM, De Stefano N, Narayanan S, et al,. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 1998; 18: 327-336. (Pubitemid 28488949)
88. Grossman RI, Lenkinski RE, Ramer KN, et al,. MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 1992; 13: 1535-1543.
89. Matthews PM, Francis G, Antel J, et al,. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis [published correction appears in Neurology 1991;41:1828:]. Neurology 1991; 41: 1251-1256.
90. Davie CA, Hawkins CP, Barker GJ, et al,. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117 part 1 49-58. (Pubitemid 24103384)
91. Bjartmar C, Kidd G, Mörk S, et al,. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
92. Suhy J, Rooney WD, Goodkin DE, et al,. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 2000; 6: 148-155. (Pubitemid 30392111)
93. Khan O, Shen Y, Caon C, et al,. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005; 11: 646-651. (Pubitemid 41685134)
94. Okuda DT, Srinivasan R, Oksenberg JR, et al,. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009; 132: 250-259.
95. Nicoli F, Vion-Dury J, Confort-Gouny S, et al,. Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy. C R Acad Sci III 1996; 319: 623-631. (Pubitemid 26334762)
96. Simone IL, Federico F, Trojano M, et al,. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. J Neurol Sci 1996; 144: 182-190. (Pubitemid 27019176)
97. Fonalledas Perellõ MA, Politi JV, Dallo Lizarraga MA, et al,. The cerebrospinal fluid lactate is decreased in early stages of multiple sclerosis. P R Health Sci J 2008; 27: 171-174.
98. Aasly J, GÃrseth M, Sonnewald U, et al,. Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis. Acta Neurol Scand 1997; 95: 9-12. (Pubitemid 27094774)
99. Gustafsson MC, Dahlqvist O, Jaworski J, et al,. Low choline concentrations in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. AJNR Am J Neuroradiol 2007; 28: 1306-1312. (Pubitemid 47309664)
100. Fernando KT, McLean MA, Chard DT, et al,. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004; 127: 1361-1369. (Pubitemid 38745514)
101. Brand A, Richter-Landsberg C, Leibfritz D., Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993; 15: 289-298. (Pubitemid 24258162)
102. Srinivasan R, Sailasuta N, Hurd R, et al,. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005; 128: 1016-1025. (Pubitemid 40675457)
103. Kim JY, Shen S, Dietz K, et al,. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 2010; 13: 180-189.
104. Pitt D, Nagelmeier IE, Wilson HC, et al,. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003; 61: 1113-1120. (Pubitemid 37461947)
105. Matute C., Oligodendrocyte NMDA receptors: a novel therapeutic target. Trends Mol Med 2006; 12: 289-292. (Pubitemid 44110002)
106. Baranzini SE, Srinivasan R, Khankhanian P, et al,. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 2010; 133: 2603-2611.
107. Kiferle L, Politis M, Muraro PA, et al,. Positron emission tomography imaging in multiple sclerosis-current status and future applications. Eur J Neurol 2011; 18: 226-231.
108. Schiepers C, Van Hecke P, Vandenberghe R, et al,. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 1997; 3: 8-17. (Pubitemid 27234858)
109. Banati RB, Newcombe J, Gunn RN, et al,. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123 part 11 2321-2337.
110. Wilms H, Claasen J, Röhl C, et al,. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol Dis 2003; 14: 417-424. (Pubitemid 37543520)
111. Blinkenberg M, Rune K, Jensen CV, et al,. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology 2000; 54: 558-564. (Pubitemid 30082918)
112. Wang Y, Wu C, Caprariello AV, et al,. In vivo quantification of myelin changes in the vertebrate nervous system. J Neurosci 2009; 29: 14663-14669.
113. Dziedzic T, Metz I, Dallenga T, et al,. Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol 2010; 20: 976-985.
114. Smith KJ., Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy [published correction appears in Brain Pathol 2007;17:345:]. Brain Pathol 2007; 17: 230-242. (Pubitemid 46466142)
115. Nicot A, Ratnakar PV, Ron Y, et al,. Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction. Brain 2003; 126: 398-412. (Pubitemid 36172744)
116. Nicot A, Kurnellas M, Elkabes S., Temporal pattern of plasma membrane calcium ATPase 2 expression in the spinal cord correlates with the course of clinical symptoms in two rodent models of autoimmune encephalomyelitis. Eur J Neurosci 2005; 21: 2660-2670. (Pubitemid 40835109)
117. Kurnellas MP, Nicot A, Shull GE, et al,. Plasma membrane calcium ATPase deficiency causes neuronal pathology in the spinal cord: a potential mechanism for neurodegeneration in multiple sclerosis and spinal cord injury. FASEB J 2005; 19: 298-300. (Pubitemid 40189288)
118. Nave KA, Trapp BD., Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008; 31: 535-561.
119. Stys PK., White matter injury mechanisms. Curr Mol Med 2004; 4: 113-130. (Pubitemid 38425909)
120. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119: 182-192.
121. Giuliani F, Goodyer CG, Antel JP, et al,. Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol 2003; 171: 368-379. (Pubitemid 36745310)
122. Vogt J, Paul F, Aktas O, et al,. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol 2009; 66: 310-322.
123. Babbe H, Roers A, Waisman A, et al,. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192: 393-404. (Pubitemid 30629164)
124. + T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004; 103: 4222-4231. (Pubitemid 38685367)
125. + T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 2004; 101: 2428-2433. (Pubitemid 38269328)
126. Neumann H, Medana IM, Bauer J, et al,. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25: 313-319. (Pubitemid 34667013)
127. Medana I, Martinic MA, Wekerle H, et al,. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001; 159: 809-815. (Pubitemid 32847171)
128. Van Oosten BW, Lai M, Hodgkinson S, et al,. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997; 49: 351-357.
129. Hohlfeld R, Wiendl H., The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001; 49: 281-284. (Pubitemid 32202778)
130. Paolillo A, Coles AJ, Molyneux PD, et al,. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999; 53: 751-757. (Pubitemid 29448295)
131. Jurewicz A, Biddison WE, Antel JP., MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J Immunol 1998; 160: 3056-3059. (Pubitemid 28136763)
132. + T cells causes axonal loss. Am J Pathol 2009; 175: 1160-1166.
133. Cappellano G, Orilieri E, Comi C, et al,. Variations of the perforin gene in patients with multiple sclerosis. Genes Immun 2008; 9: 438-444.
134. Matusevicius D, Kivisäkk P, Navikas V, et al,. Interleukin-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis. Scand J Immunol 1998; 47: 582-590. (Pubitemid 28273369)
135. Rubesa G, Podack ER, Sepcić J, et al,. Increased perforin expression in multiple sclerosis patients during exacerbation of disease in peripheral blood lymphocytes. J Neuroimmunol 1997; 74: 198-204. (Pubitemid 27128995)
136. Kivisäkk P, Stawiarz L, Matusevicius D, et al,. High numbers of perforin mRNA expressing CSF cells in multiple sclerosis patients with gadolinium-enhancing brain MRI lesions. Acta Neurol Scand 1999; 100: 18-24. (Pubitemid 29292547)
137. Deb C, Lafrance-Corey RG, Zoecklein L, et al,. Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis. J Neuropathol Exp Neurol 2009; 68: 1037-1048.
138. Derfuss T, Parikh K, Velhin S, et al,. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A 2009; 106: 8302-8307.
139. Bartos A, Fialová L, Soukupová J, et al,. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 2007; 254: 20-25. (Pubitemid 46295063)
140. Rawes JA, Calabrese VP, Khan OA, et al,. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases. Mult Scler 1997; 3: 363-369. (Pubitemid 28040877)
141. Mathey EK, Derfuss T, Storch MK, et al,. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007; 204: 2363-2372. (Pubitemid 47529322)
142. Moffett JR, Ross B, Arun P, et al,. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89-131. (Pubitemid 46282272)
143. Hulshagen L, Krysko O, Bottelbergs A, et al,. Absence of functional peroxisomes from mouse CNS causes dysmyelination and axon degeneration. J Neurosci 2008; 28: 4015-4027.
144. Kassmann CM, Lappe-Siefke C, Baes M, et al,. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 2007; 39: 969-976. (Pubitemid 47185174)
145. Dietz KC, Casaccia P., HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res 2010; 62: 11-17.